Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Cancer Pain 4Pain, Intractable 3Pain 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Fentanyl 23Analgesia 22Morphine 19Acupuncture Therapy 18Zoledronic Acid 15Oxycodone 14Acetaminophen 14Ketamine 13Radiotherapy 12Therapeutics 11Methadone 11Lidocaine 11nabiximols 10Ibandronic Acid 10Hydromorphone 10Bupivacaine 10Surveys and Questionnaires 8Ropivacaine 8Psychiatric Rehabilitation 7Early Intervention, Educational 7Saline Solution 6Music Therapy 6Cryotherapy 6Cryosurgery 6Yoga 5Water 5Tapentadol 5Pregabalin 5Methods 5Massage 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pain × resiniferatoxin × Clear all
NCT05067257 2024-03-18

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Sorrento Therapeutics, Inc.

Phase 2 Suspended
120 enrolled

Cancer Pain, Pain, Pain, Intractable

NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡